Key result
Obicetrapib 10 mg had a numerically lower rate of new-onset diabetes vs placebo (6.4% vs 8.5%; OR 0.69, 95% CI 0.47-1.03), while CETP inhibition overall reduced risk by 16% (RR 0.84, 95% CI 0.79-0.90).
Why the study?
New-onset diabetes is a recognised effect of statin therapy, whereas CETP inhibition has been associated with lower risk in earlier trials. This study assessed the effect of the highly selective CETP inhibitor obicetrapib on glycaemia and new-onset diabetes within an updated meta-analysis of CETP inhibitor trials.
Does obicetrapib 10 mg and CETP inhibition as a class reduce the risk of new-onset diabetes or adversely affect glycaemia compared with placebo in patients without diabetes at baseline?
Meta-Analysis (n=1,700)
2:1
Does obicetrapib 10 mg and CETP inhibition as a class reduce the risk of new-onset diabetes or adversely affect glycaemia compared with placebo in patients without diabetes at baseline?
Odds Ratio: 0.69 (95% CI 0.47–1.03)
Absolute Event Rate: 6.4% vs 8.5%
Obicetrapib does not adversely affect glycaemic control over 52 weeks and shows a numerical reduction in new-onset diabetes that aligns with a protective class effect of CETP inhibitors.
AIMS: New-onset diabetes (NoD) is a recognised effect of statin therapy potentially influencing acceptance of intensive LDL-C-lowering. In contrast, cholesteryl ester transfer protein (CETP) inhibition has been associated with lower NoD risk in earlier trials. We assessed the effect of the highly selective CETP inhibitor obicetrapib on glycaemia and NoD, contextualised within an updated meta-analysis of CETP inhibitor trials. METHODS: Individual participant data from the phase 3 BROADWAY and BROOKLYN trials were pooled across 1,700 participants without diabetes at baseline (899 normoglycaemic, 801 prediabetes; 38.8% women), randomised 2:1 to obicetrapib 10 mg or placebo for 52 weeks. The PRISMA-compliant, PROSPERO-registered systematic review identified six eligible trials reporting NoD. Pooled risk ratios were calculated using Mantel-Haenszel fixed-effect models, with prespecified subgroup analyses by baseline glycaemic status and CETPi potency, and trial-level meta-regression. RESULTS: Obicetrapib did not increase HbA1c at week 52 vs placebo (LSMD -0.02%, 95% CI -0.04 to 0.00). NoD occurred in 6.4% (obicetrapib) versus 8.5% (placebo) (adjusted OR 0.69, 95% CI 0.47-1.03), directionally consistent across glycaemic strata. Restricted cubic spline analyses identified associations between HDL-C, apoA1 and Lp(a) changes and NoD risk, but not HbA1c change. In the meta-analysis, CETP inhibition was associated with a 16% lower risk of NoD (RR 0.84, 95% CI 0.79-0.90; I2 = 0%). CONCLUSIONS: Obicetrapib did not adversely affect glycaemia and was associated with a numerically lower risk of NoD, consistent with a CETP inhibitor class signal of a modestly lower risk. The PREVAIL trial will provide larger-longer evidence about obicetrapib and NoD.
No takes yet. Share an insight, caveat, or question.
Brandts et al. (2026) conducted a meta-analysis in New-onset diabetes and glycaemia in participants without baseline diabetes (n=1,700). Obicetrapib vs. Placebo was evaluated on New-onset diabetes (NoD) (adjusted OR 0.69, 95% CI 0.47-1.03). Obicetrapib 10 mg had a numerically lower rate of new-onset diabetes vs placebo (6.4% vs 8.5%; OR 0.69, 95% CI 0.47-1.03), while CETP inhibition overall reduced risk by 16% (RR 0.84, 95% CI 0.79-0.90).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: